Physician profile
Brian D Carlson
NPI 1740420439
$9,266.94
in general payments reported to CMS, 2019-2025
55 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,351 · 2021: $2,057 · 2022: $1,480 · 2023: $1,022 · 2024: $1,169 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,865 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,368.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $752.02 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $605.54 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $555.51 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.74 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $487.65 | 2021-2024 | |
| Lilly USA, LLC | $455.21 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $435.89 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $395.04 | 2020-2024 | Nexletol |
| Gilead Sciences, INC. | $328.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $263.68 | 2019-2025 | Leqvio |
| Abbvie INC. | $245.20 | 2021-2022 | |
| Exact Sciences Corporation | $232.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $225.17 | 2019-2024 | |
| Astellas Pharma US INC | $217.01 | 2019-2024 | Veozah |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.